Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer
Titel:
Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer
Auteur:
Ellis, M.J. Sing, B. Miller, W.R. Llombart-Cussac, A. Janicke, F. Evans, D.B. Borgs, M. Quebe-Fehling, E. Brady, C. Dugan, M. Coop, A.